S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Latest Information Update: 17 Jan 2025
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Cetuximab; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms MyPathway
Most Recent Events
- 14 Jan 2025 Planned End Date changed from 20 Nov 2024 to 30 Nov 2025.
- 16 Jan 2024 Planned End Date changed from 15 Jun 2024 to 20 Nov 2024.
- 21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium